KLRK1 and type 1 diabetes mellitus: Blevins’ [88] team isolated NKG2D soluble ligand (sRAE-1) plasmid DNA and delivered a therapeutic plasmid targeting the pancreas, which reduced the interaction between β cells and infiltrating NKG2D-positive lymphocytes, thereby effectively protecting β cells from autoimmune destruction and preventing T1DM.